2015
DOI: 10.1007/s00404-015-3691-4
|View full text |Cite
|
Sign up to set email alerts
|

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study

Abstract: This BRENDA sub-group analysis, on a German cohort of breast cancer patients confirmed the negative outcome of IBC and the different clinical behavior of IBC subtypes. The best management of IBC requires intensive coordination and cooperation between various clinical disciplines involved in the treatment of IBC patients. Moreover there is a need to identify IBC-specific targeted therapies to improve the curing prospects of this subtype of cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
5
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 49 publications
0
5
0
Order By: Relevance
“…In this retrospective multi-centre cohort study of the BRENDA (= breast cancer care under evidence-based guidelines) study group, we extracted data from 1376 nodal-positive patients with luminal A breast cancer patients at the Department of Gynecology and Obstetrics at the University of Ulm and 16 partner hospitals (all certified breast cancer centres) in Baden-Wuerttemberg (Germany) for the period 2001-2008. The exact conditions and inclusion criteria of BRENDA have been described previously [11,12]. Patients receiving chemotherapy have been administered to antracyclins and/or taxans.…”
Section: Methodsmentioning
confidence: 99%
“…In this retrospective multi-centre cohort study of the BRENDA (= breast cancer care under evidence-based guidelines) study group, we extracted data from 1376 nodal-positive patients with luminal A breast cancer patients at the Department of Gynecology and Obstetrics at the University of Ulm and 16 partner hospitals (all certified breast cancer centres) in Baden-Wuerttemberg (Germany) for the period 2001-2008. The exact conditions and inclusion criteria of BRENDA have been described previously [11,12]. Patients receiving chemotherapy have been administered to antracyclins and/or taxans.…”
Section: Methodsmentioning
confidence: 99%
“…The exact conditions and inclusion criteria of BRENDA have been described previously [22, 23]. For this retrospective study, we extracted data from 4570 patients with luminal A tumors.…”
Section: Methodsmentioning
confidence: 99%
“…A definitive diagnosis of IBC is made in a patient with these clinical symptoms and short timeline coupled with pathologic confirmation of invasive carcinoma3. Although IBC has a low incidence (about 2% in the United States124), it is the most lethal form of breast cancer with a median survival of approximately 4 years compared to >10 years for other non-inflammatory breast cancers (nIBC)456. A key characteristic of IBC distinguishing it from nIBC is IBC’s propensity for metastasis.…”
mentioning
confidence: 99%
“…A key characteristic of IBC distinguishing it from nIBC is IBC’s propensity for metastasis. Essentially all IBC patients present with lymph node involvement and one-third of patients already have distant metastasis at initial diagnosis1256. The survival curves for metastatic nIBC and non-metastatic IBC are nearly identical the first five years post diagnosis, further highlighting IBC’s characteristic lethality and rapid metastasis7.…”
mentioning
confidence: 99%
See 1 more Smart Citation